Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)

NCT00850616 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

147

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV
HIV Infections

Interventions

BIOLOGICAL: V526
BIOLOGICAL: Comparator: Placebo to V526

Sponsor

Merck Sharp & Dohme LLC